Trebellar raises $18M Series A. Trebellar raises $18M in Series A funding led by Blossom Capital to scale its AI-native platform for corporate real estate management. Updated September 24, 2026 Trebellar, a San Francisco-based company providing an AI-native platform for corporate real estate management, has announced $18 million in Series A funding. The platform helps large enterprises manage complex real estate portfolios by synthesizing data from disparate sources into a single, actionable system of record. Investors. The funding round was led by Blossom Capital, with participation from Haystack, Alt Capital, 1Flourish, and Bynd. Trebellar use of funds. The company plans to use the new capital to scale its engineering and go-to-market teams, enhance its artificial intelligence capabilities, and expand its customer base among global enterprises. About trebellar. Founded by Diego Ferreiro Val and David Garcia Quintas, Trebellar provides AI-native decision-making software for corporate real estate. Its platform creates a live view of an organization's real estate portfolio, helping teams understand space, costs, utilization, and workplace needs while maintaining a record of decisions and their outcomes. Funding details. Company: Trebellar Raised: $18M Round: Series A Funding Date: September 24, 2026 Lead Investor: Blossom Capital Additional Investors: Haystack, Alt Capital, 1Flourish, Bynd Company Website: trebellar.com Software Category: PropTech Source: https://www.morningstar.com/news/business-wire/20260924253792/trebellar-raises-18m-series-a-to-bring-ai-to-corporate-real-estate-management Updated September 24, 2026

2026 funding rounds for AI data platforms, robotics humanoids and genomic AI. A roundup of recent seed, series and pre-seed financings across AI, robotics and genetic-engineering firms, detailing investors, amounts and intended use of capital. Compiled automatically from the sources listed below and checked against Hyperuranios' own capital and research data. Every figure here traces to a linked source. Factual errors reported to the contact address are corrected in the article and noted here. Artificial intelligence. Codebreaker Labs, a Boulder-based genomic AI startup, closed a $4.5 million seed round that was led by Kickstart with continued backing from Buff Gold Ventures and Children's Hospital Colorado, and new participation from Denver Ventures, Service Provider Capital and Pelican Trust. The capital will fund laboratory scale-up, scientific hires and the creation of its first variant Atlases and AI interpretation tools, aiming to generate functional evidence for 100,000 genomic variants by 2027. The round places the deal in the top fifth of US seed rounds by size. [1] Snorkel AI announced a $350 million raise that follows an annualised revenue run-rate of $375 million after its data-as-a-service offering grew more than 18-fold since launch. The funding will be deployed to expand its agentic data development platform, invest in vertical and enterprise AI applications, and broaden research into new domains and modalities, including open benchmarking and evaluation environments. Snorkel positions the round as a shift from volume-led Data 1.0 to high-quality, expert-driven Data 2.0. [3] Trebellar secured $18 million in a Series A round led by Blossom Capital, with participation from Haystack, Alt Capital, 1Flourish and Bynd. The San Francisco-based firm will use the proceeds to grow its engineering and go-to-market teams, deepen its AI capabilities for corporate real-estate decision-making and expand its enterprise customer base, which already includes Meta, Uber, Merck and Cohesity. The capital is intended to build an AI-native data layer that aggregates lease, occupancy and HR data for automated portfolio analysis. [4] Modal Labs is in talks to raise new capital at a $15 billion valuation, nearly tripling its $4.65 billion valuation from a $355 million raise in May. The earlier round was led by General Catalyst and Redpoint Ventures, with Accel, Menlo Ventures and Bain Capital Ventures also participating, bringing total funding to about $465 million. The company plans to use the anticipated money to scale its AI-inference infrastructure, which offers per-second GPU and CPU billing and a Sandboxes product for AI coding agents, as inference now accounts for roughly two-thirds of AI computing demand. [5] Enveda raised $311 million in a Series E round that values the biotech at $2 billion. The round was led by Catalio Capital Management with participation from Iconiq and other investors. The infusion will advance Enveda's nature-derived AI drug candidates into clinical trials, focusing on severe skin conditions and weight-management therapies. By leveraging AI to analyse natural product data, the company aims to streamline discovery and reduce time-to-clinic for its plant- and microbe-based medicines. [7] Snorkel AI announced a $350 million raise that follows an annualised revenue run-rate of $375 million after its data-as-a-service offering grew more than 18-fold since launch. The funding will be deployed to expand its agentic data development platform, invest in vertical and enterprise AI applications, and broaden research into new domains and modalities, including open benchmarking and evaluation environments. Snorkel positions the round as a shift from volume-led Data 1.0 to high-quality, expert-driven Data 2.0. [3] Dextr AI secured $6.7 million in a seed round led by Elevation Capital, with participation from Foundational Capital. The funds will accelerate product development, expand the in-house team and scale platform deployments across international hospitality markets, notably India. The AI agents platform automates guest-experience, booking and back-of-house workflows, handling over one million interactions monthly and processing tens of millions of dollars in phone bookings for clients such as Hilton, Wyndham and IHG. [10] Metis Reasoning, the AI startup founded by AlphaGo co-creator Thore Graepel, is in early fundraising talks targeting a first check in the tens of millions of dollars, with the possibility of a larger tranche in the hundreds of millions later. The venture, which aims to build AI capable of confronting novel situations for robotics, scientific work and engineering, is leveraging Graepel's reputation from AlphaGo to attract a tight early investor group. No final round size has been disclosed. [6] Robotics. Feather Robotics raised $7.6 million in a seed round led by Gradient, with Builder Capital, Geometry, Seed Innovation and Virgo VC also participating. The San Francisco-based company will use the capital to commercialise its developer-focused wheeled humanoid robot priced at $29,990, featuring two seven-degree-of-freedom arms, an omnidirectional base and ten-hour battery life. The funding supports scaling production of an affordable physical-AI platform intended to become a common hardware foundation for robotics developers. [2] Feather Robotics, backed initially by Gradient Ventures, announced that its $7.6 million pre-seed funding has enabled the company to generate over $1 million in revenue and ship its $30,000 modular humanoid robot to customers using it as cooks, lab assistants and more. The robot runs models from leading AI providers and can be customised with interchangeable arms and sensors. The company plans a larger product launch after resolving field-testing issues, positioning the platform as an open hardware ecosystem for physical-AI applications. [8] Genetic engineering. Codebreaker Labs, a Boulder-based genomic AI company, closed a $4.5 million seed round that was led by Kickstart with continued backing from Buff Gold Ventures and Children's Hospital Colorado, and new participation from Denver Ventures, Service Provider Capital and Pelican Trust. The capital will fund laboratory scale-up, scientific hires and the creation of its first variant Atlases and AI interpretation tools, aiming to generate functional evidence for 100,000 genomic variants by 2027. The round places the deal in the top fifth of US seed rounds by size. [1] Enveda raised $311 million in a Series E round that values the biotech at $2 billion. The round was led by Catalio Capital Management with participation from Iconiq and other investors. The infusion will advance Enveda's nature-derived AI drug candidates into clinical trials, focusing on severe skin conditions and weight-management therapies. By leveraging AI to analyse natural product data, the company aims to streamline discovery and reduce time-to-clinic for its plant- and microbe-based medicines. [7] The Gene Editing Market Outlook 2026-2030 report highlights expanding CRISPR applications beyond medicine into agriculture, industrial biotechnology and diagnostics, noting that gene-editing technologies are driving new commercial pathways across multiple sectors. The analysis points to growing investment, regulatory engagement and scientific breakthroughs as key drivers, while emphasizing the need for realistic expectations about commercialization timelines. No specific funding event is detailed, but the report underscores the sector's increasing strategic relevance. [9]